Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $9.267 million which missed the analyst consensus estimate of $21.533 million by 56.96 percent. This is a 347.90 percent increase over sales of $2.069 million the same period last year.
Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.